Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2022 16:07 ET | Source: Instil Bio

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First...
November 08, 2022 07:00 ET | Source: Instil Bio

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
October 31, 2022 07:00 ET | Source: Instil Bio

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actionsNo regulatory agency, including the FDA, has notified...
October 18, 2022 07:00 ET | Source: Instil Bio

Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer

• ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment • CoStAR-T...
September 19, 2022 07:20 ET | Source: Instil Bio

Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
September 09, 2022 07:00 ET | Source: Instil Bio

Instil Bio to Present at Morgan Stanley Global Healthcare Conference

DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
September 06, 2022 07:00 ET | Source: Instil Bio

Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
August 12, 2022 07:00 ET | Source: Instil Bio

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational...
May 27, 2022 07:00 ET | Source: Instil Bio

Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment

FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancerInstil to present in vivo data with CoStAR T cells...
May 18, 2022 07:00 ET | Source: Instil Bio

Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)

DALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...